Genedrive
Genedrive is a Manchester-based pharmacogenetic diagnostics company that sells a point-of-care molecular platform and test kits to the UK NHS, enabling rapid bedside genetic testing for neonatal antibiotic safety and stroke antiplatelet therapy selection.
- Company typePublic
- Founded2016
- HeadquartersManchester, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Genedrive does
Genedrive Diagnostics Ltd is a Manchester-based pharmacogenetic testing company that develops and commercialises a point-of-care molecular diagnostic platform, the Genedrive® System, which delivers genetic test results at the bedside in approximately one hour. The platform supports two flagship assays: the MT-RNR1 ID Kit, which identifies infants at risk of antibiotic-induced hearing loss to inform aminoglycoside prescribing in neonatal intensive care, and the CYP2C19 ID Kit, which detects variants affecting clopidogrel metabolism to guide personalised antiplatelet therapy in stroke patients. Both assays were developed and validated in collaboration with NHS partners, and NHS Implementation Guides have been published for both products.
The company's commercial model is built on a hardware-plus-consumables razor-and-blade structure: it sells or places the Genedrive System instrument with NHS trusts and health boards and generates recurring revenue through ongoing sales of single-use test cartridges. Go-to-market is enterprise field sales targeting NHS neonatal units and stroke services, supported by clinical pilot programmes, implementation guides, and partnerships with Health Innovation Manchester, the University of Manchester, and the NHSE Network of Excellence in Pharmacogenetics. Pricing is not publicly disclosed and follows a quote-based model typical of medical-device procurement by NHS institutions. Strategic priorities include geographic expansion into Europe, the Middle East, and the US — with an FDA 510(k) submission for the CYP2C19 test anticipated around June 2026 — alongside manufacturing scale-up and product development, funded in part by a cluster of equity raises in 2024 and February 2026 totaling up to approximately £13 million, with insider participation from CEO Dr. Gino Miele, CFO Russ Shaw, and major shareholders David Nugent and Robert English.
Genedrive firmographics
Firmographics- Name
- Genedrive
- Legal name
- Genedrive Diagnostics Ltd
- Website
- https://genedriveplc.com
- Company type
- Public
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Genedrive is a Manchester-based pharmacogenetic diagnostics company that sells a point-of-care molecular platform and test kits to the UK NHS, enabling rapid bedside genetic testing for neonatal antibiotic safety and stroke antiplatelet therapy selection.
- Ownership category
- akta.pro rank
Genedrive industry classification
Industry- Product category
- Molecular Diagnostics
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Pharmacogenomics-Informed Medication Optimization Support (HSABALAO)
Keywords
Where Genedrive is headquartered
LocationHeadquarters
- HQ city
- Manchester
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Genedrive business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
Revenue model
- Genedrive System Hardware Sales: Sale of the Genedrive molecular diagnostic instrument/platform to healthcare institutions. The system serves as the hardware platform upon which test kits are run.
- Test Kit Consumables: Recurring sales of MT-RNR1 ID Kit and CYP2C19 ID Kit test cartridges/consumables to NHS and healthcare customers as they conduct ongoing patient testing.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
Genedrive product offering
Product offeringCore offering
Genedrive develops and commercialises a point-of-care molecular diagnostic platform (the Genedrive® System) that runs single-use pharmacogenetic test cartridges. Its two flagship kits — the MT-RNR1 ID Kit for personalised antibiotic selection in neonatal intensive care and the CYP2C19 ID Kit for personalised antiplatelet therapy in stroke — are sold to NHS trusts and other healthcare institutions, delivering genetic results in approximately one hour at the bedside.
Product overview
Genedrive is a pharmacogenetic testing company offering a point-of-care molecular diagnostic platform (Genedrive® System) with two flagship test kits: the MT-RNR1 ID Kit for personalised antibiotic treatment in neonates, and the CYP2C19 ID Kit for personalised antiplatelet treatment in stroke patients. The platform enables rapid genetic testing at the bedside within time-critical healthcare settings, with both products developed and validated in collaboration with NHS partners.
Differentiator
Problem solved
Functional benefit
Brands
- Genedrive System: Molecular diagnostic platform for rapid pharmacogenetic testing at point of need.
Products and services
- Genedrive® System
Quantifiable outcome
- Results delivered in approximately 1 hour vs days for traditional lab testing
Companies that use Genedrive
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles2 records
Genedrive technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Genedrive partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- Manchester NHS Industry Partnership ProgrammecoreMulti-partner grant initiative to validate the CYP2C19 ID Kit in NHS settings requiring rapid genomic testing. Part of a Manchester NHS Industry Partnership Programme focused on improving time-critical diagnostics in healthcare.
- Health Innovation ManchestercoreStrategic partnership with Health Innovation Manchester to support sustained deployment of the MT-RNR1 test across Greater Manchester. The partnership involves academic and health partners to ensure implementation across all neonatal sites in the region.
- University of ManchestercoreAcademic partnership with University of Manchester for translational genomic medicine research and the NHSE Network of Excellence in Pharmacogenetics and Medicines Optimisation.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
Genedrive competitors and assessment
Company assessmentBroad incumbents
- Cepheid (bioMérieux): Leading molecular diagnostics platform (GeneXpert) widely deployed across hospitals including the NHS. Comparable as a point-of-care/hospital molecular diagnostics company; broader portfolio and deeper global footprint, but overlapping use cases in rapid genetic and infectious disease testing.
- QIAGEN: Global molecular diagnostics and sample-preparation company with a broad pharmacogenetics and infectious disease portfolio. Comparable in underlying molecular diagnostic technology, though operates at much larger scale across both research and clinical markets.
- BioFire Diagnostics (bioMérieux): Subsidiary of bioMérieux offering rapid syndromic and molecular diagnostics used in hospital and emergency settings. Comparable in delivering rapid, panel-based molecular diagnostic results at the point of care within clinically actionable timeframes.
- GenMark Diagnostics (Roche): Now part of Roche, provides rapid molecular diagnostic systems (e.g., ePlex) for hospital and emergency care use. Comparable in deploying multi-analyte molecular panels at the hospital point of care, often in critical care and stroke workflows.
- Mesa Labs: Acquired Agilent's molecular diagnostics and pharmacogenomics business (formerly GenMark Dx and others); provides clinical molecular testing platforms. Comparable in offering molecular diagnostics with pharmacogenomics focus into hospital and reference lab settings.
- Thermo Fisher Scientific (Clinical Diagnostics): Global life sciences company with a clinical diagnostics division offering molecular testing instruments, reagents, and pharmacogenomics solutions. Comparable as a broad incumbent enabling hospital and reference-lab molecular and PGx testing at significantly larger scale.
Direct peers
- QuantuMDx: UK-based developer of a point-of-care molecular diagnostic platform (Q-POC) with similar focus on rapid, decentralised genetic testing. Directly comparable business model and target customer base (hospitals, including NHS-adjacent markets).
- Randox: UK-headquartered diagnostics company with point-of-care and clinical laboratory molecular testing capabilities, including pharmacogenetics offerings. Comparable as a UK diagnostics peer serving NHS and international hospital markets.
- Spartan Bioscience: Canadian developer of a point-of-care DNA testing platform (Spartan Cube) with pharmacogenomics and infectious disease applications. Closely comparable in delivering rapid, cartridge-based molecular diagnostics at the bedside for personalised medicine use cases.
Emerging players
- DxTerity Diagnostics: US-based molecular diagnostics company with focus on pharmacogenomics and immune-related testing. Comparable in offering clinical-grade PGx testing, though primarily centralised laboratory rather than point-of-care delivery.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Genedrive social profiles
Digital presenceGenedrive financial estimates
Financial estimateRevenue estimate
Valuation estimate
Genedrive leadership team
Management profileNumber of profiles
Profiles4 records
Genedrive funding detail
Funding detailFunding overview
Funding rounds4 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Genedrive M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Genedrive
What does Genedrive do?
Genedrive develops and commercialises a point-of-care molecular diagnostic platform (the Genedrive® System) that runs single-use pharmacogenetic test cartridges. Its two flagship kits — the MT-RNR1 ID Kit for personalised antibiotic selection in neonatal intensive care and the CYP2C19 ID Kit for personalised antiplatelet therapy in stroke — are sold to NHS trusts and other healthcare institutions, delivering genetic results in approximately one hour at the bedside.
Is Genedrive a public or private company?
Genedrive is a public company. It is classified as public and is currently operating.
When was Genedrive founded?
Genedrive was founded in 2016. It employs 11 to 50 people.
Where is Genedrive based?
Genedrive is headquartered in Manchester, United Kingdom, in the Europe region.
How does Genedrive make money?
Two revenue lines are on record. Genedrive System Hardware Sales are the primary driver. The others are test Kit Consumables.
Who are Genedrive's main competitors?
Broad incumbents on record are Cepheid (bioMérieux), QIAGEN, BioFire Diagnostics (bioMérieux), GenMark Diagnostics (Roche), Mesa Labs and Thermo Fisher Scientific (Clinical Diagnostics). Direct peers are QuantuMDx, Randox and Spartan Bioscience. DxTerity Diagnostics is listed as an emerging player.
Does Genedrive have an API?
No public API is recorded for Genedrive.
What industry is Genedrive in?
Genedrive's product category is Molecular Diagnostics. Its primary akta.pro industry code is HSABALAO, Pharmacogenomics-Informed Medication Optimization Support. Its NAICS code is 334510 and its SIC code is 3841.